Vol. 7, Issue 1, Part A (2025)

Non-alcoholic fatty liver disease is now a major issue due to its numerous cases, challenging diagnosis, complex pathogenesis, and lack of authorized treatments. Irisin, a newly discovered myokine, increases total energy expenditure by acting on white adipose tissue cells, which regulates glucose homeostasis and obesity. This study compared the levels of serum irisin, GGT, liver enzyme, lipid profile, albumin, and bilirubin in patients with nonalcoholic fatty liver disease (NAFLD) to those of healthy controls. 
Between January and March 2023, our institute received 30 health screen examinees, and 60 patients were enrolled based on their history of alcohol use, blood tests, abdominal ultrasonography results, and if they gave written informed consent. age, sex, and the results of laboratory tests; Patients with NAFLD exhibited significantly higher blood GGT levels (282.17±75.97 vs. 160.06±46.30, p=0.001) and serum ALT levels (44.13±6.53 vs. 33.66±6.60, p>0.001). NAFLD patients exhibited significantly higher mean serum AST levels than the control group (46.77±7.73 versus 32.91±6.22) (p>0.001). NAFLD patients had significantly higher serum lipid profiles (TG and cholesterol) compared to controls (215.99±15.44 vs 189.75±9.16) and (198.47±25.44 vs 157.74±30.40) (mg/dL), with p values <0.001. Patients with NAFLD had significantly higher Irsin concentrations compared to controls (5.7±0.75 vs 0.9±0.3), with p-values < 0.001. Serum albumin (3.95±0.42 vs 6.24±0.42) and bilirubin (6.95±1.10 vs 0.78±0.07) concentrations were significantly lower (3.95±0.42 vs 6.24±0.42) than controls, with p values < 0.001, respectively.
Aim of the study: This study aimed to assess the levels of lipid profiles (TG and total cholesterol), albumin and bilirubin, liver enzymes (AST and ALT), and blood levels of irisin in patients with non-alcoholic fatty liver disease (NAFLD) in comparison to control groups.